Source: EURLEX
Language: en
Format: md

Judgment of the General Court (Third Chamber) of 18 November 2020 –  
Allergan Holdings France v EUIPO – Dermavita (JUVEDERM ULTRA)

(Case T‑664/19)

(EU trade mark – Revocation proceedings – EU word mark JUVEDERM ULTRA – Genuine use of the mark – Use in connection with the goods in respect of which the mark was registered – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))

| 1. | EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Proof of use – Burden of proof  (Council Regulation No 207/2009, Art. 51)  (see para. 18) |

| 2. | EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Word mark JUVEDERM ULTRA  (Council Regulation No 207/2009, Art. 15(1)(a))  (see paras 19, 20) |

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France.

Operative part

The Court:

| 1. | Dismisses the action; |

| 2. | Orders Allergan Holdings France to pay the costs. |

[Top](#document1)